COVID-19 in hematopoietic cell transplant recipients

Basit Öğe Kaydı
dc.authoridBERBER, Ilhami/0000-0003-3312-8476
dc.authoridYigenoglu, Tugce/0000-0001-9962-8882
dc.authoridBirinci, Suayip/0000-0001-8104-6198
dc.authoridDogu, Mehmet Hilmi/0000-0001-7237-2637
dc.authoridBasturk, Abdulkadir/0000-0003-1864-0316
dc.authoridErkurt, Mehmet Ali/0000-0002-3285-417X
dc.authoridBaşcı, Semih/0000-0003-4304-9245
dc.authorwosidBERBER, Ilhami/ABI-6231-2020
dc.authorwosidYigenoglu, Tugce/ABF-6595-2021
dc.authorwosidBirinci, Suayip/JFJ-4049-2023
dc.authorwosidCelik, Osman/KLZ-6766-2024
dc.authorwosidDogu, Mehmet Hilmi/W-2255-2017
dc.authorwosidBasturk, Abdulkadir/B-1962-2018
dc.authorwosidErkurt, Mehmet Ali/ABI-7232-2020
dc.contributor.authorAltuntas, Fevzi
dc.contributor.authorAta, Naim
dc.contributor.authorYigenoglu, Tugce Nur
dc.contributor.authorBasci, Semih
dc.contributor.authorDal, Mehmet Sinan
dc.contributor.authorKorkmaz, Serdal
dc.contributor.authorNamdaroglu, Sinem
dc.date.accessioned2024-08-04T20:49:03Z
dc.date.available2024-08-04T20:49:03Z
dc.date.issued2021
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn this study, we aim to report the outcome of COVID-19 in hematopoietic cell transplant (HCT) recipients. HCT recipients (n = 32) with hematological disease and hospitalized for COVID-19 were included in the study. A cohort of age and comorbid disease-matched hospitalized COVID-19 patients with hematological malignancy but not underwent HCT (n = 465), and another cohort of age and comorbid disease-matched hospitalized COVID-19 patients without cancer (n = 497) were also included in the study for comparison. Case fatality rate (CFR) was 5.6% in patients without cancer, 11.8 in patients with hematological malignancy and 15.6% in HCT recipients. The CFR in HCT recipients who were not receiving immunosuppressive agents at the time of COVID-19 diagnosis was 11.5%, whereas it was 33% in HCT recipients who were receiving an immunosuppressive agent at the time of COVID-19 diagnosis. In conclusion, our study reveals that for the current pandemic, HCT recipients, especially those receiving immunosuppressive drugs, constitute a special population of cancer patients.en_US
dc.identifier.doi10.1038/s41409-020-01084-x
dc.identifier.endpage955en_US
dc.identifier.issn0268-3369
dc.identifier.issn1476-5365
dc.identifier.issue4en_US
dc.identifier.pmid33110186en_US
dc.identifier.scopus2-s2.0-85094131594en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage952en_US
dc.identifier.urihttps://doi.org/10.1038/s41409-020-01084-x
dc.identifier.urihttps://hdl.handle.net/11616/99603
dc.identifier.volume56en_US
dc.identifier.wosWOS:000584556900001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringernatureen_US
dc.relation.ispartofBone Marrow Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subject[No Keywords]en_US
dc.titleCOVID-19 in hematopoietic cell transplant recipientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu